Latest CSL Behring Stories

KING OF PRUSSIA, Pa., Oct. 12 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S. The approval is based on the results of the phase II/III...

KING OF PRUSSIA, Pa., March 11 /PRNewswire/ -- CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP(TM) is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven years of orphan-drug exclusivity. RiaSTAP was approved by the FDA in January and is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency,...

The U.S. Food and Drug Administration has approved RiaSTAP for the treatment of bleeding in patients with a rare genetic defect. People with the defect -- congenital fibrinogen deficiency -- are unable to make sufficient amounts of fibrinogen, which plays an important role in blood coagulation by helping to form blood clots and prevent bleeding. This product offers much-needed treatment for the small number of patients with congenital fibrinogen deficiency, said Dr. Jesse Goodman, director...

KING OF PRUSSIA, Pa., Jan. 16 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Congenital fibrinogen deficiency is a rare, potentially life-threatening bleeding disorder that affects an estimated one person per million, with an estimated...

LEIDEN, Netherlands and PARSIPPANY, N.Y., Dec. 18 /PRNewswire/ --DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6(R) platform. Under the terms of the...

HAE:TSX MONTREAL, Dec. 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value, human plasma-derived protein products for commercialization, announces that is has confirmed the successful operation qualification of the fibrin sealant production equipment at its new state-of-the-art plasma fractionation facility in Sarasota, Florida. "I am very excited that we have achieved the important milestone of operation...

CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, today announced an innovative online quick-ship ordering system, enabling healthcare providers and other purchasers to buy CSL Biotherapies' thimerosal-free flu vaccine for adults directly from the company. This new purchasing platform (accessible at www.mercuryfreefluvaccine.com) offers customers enhanced access to a thimerosal-free product in the quantity they need, whenever they need it....

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions. "CSL Behring is proud to support...

Mediware Information Systems, Inc. (NASDAQ: MEDW) announced that ZLB Plasma has licensed the Company's RecruitTrak(TM) software to support plasma donor recruitment in 65 plasma centers throughout the United States. RecruitTrak, which is one of Mediware's Blood Center Technologies (BCT) products, provides a powerful online environment to enable ZLB staff to better manage donor relationships, increase recruitment efforts and lengthen donor retention. RecruitTrak will provide ZLB Plasma CRM...

NEW YORK, Sept. 23 /PRNewswire/ -- While an estimated 2.8 million Americans are affected by the most common hereditary bleeding disorder, von Willebrand disease (VWD), most don't even know they have it. VWD affects both men and women, but according to the Centers for Disease Control and Prevention (CDC) it takes a woman an average of 16 years to receive a diagnosis. Now a group of mothers with VWD have joined together to focus attention on the need for more communication between mothers and...